1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma : a 10-year follow-up
Pulczynski, Elisa Jacobsen ; Simonsen, Mikkel Runason ; Kuittinen, Outi ; Fagerli, Unn Merete ; Erlanson, Martin ; Fluge, Øystein ; Leppä, Sirpa ; Østenstad, Bjørn ; Fosså, Alexander and Eriksson, Mikael LU
, et al.
(2024)
In Haematologica
109(7).
p.2359-2363
- Contribution to journal › Letter
- 2021
-
Mark
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
- Contribution to journal › Article
- 2020
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
- Contribution to journal › Article
- 2019
-
Mark
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
- Contribution to journal › Article
- 2016
-
Mark
PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
- Contribution to journal › Article
- 2015
-
Mark
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.
Pulczynski, Elisa J ; Kuittinen, Outi ; Erlanson, Martin ; Hagberg, Hans ; Fosså, Alexander ; Eriksson, Mikael LU
; Nordstrøm, Marie
; Ostenstad, Bjørn
; Fluge, Oystein
and Leppä, Sirpa
, et al.
(2015)
In Haematologica
100(4).
p.534-540
- Contribution to journal › Article
- 2010
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1157-1157
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
- Contribution to journal › Published meeting abstract